New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

LEUVEN, Belgium, May 2, 2017 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that its research and development team, associated experts and others will be presenting 12 papers and posters including new ophthalmic research findings at the upcoming ARVO (Association for Research in Vision and Ophthalmology) 2017 Annual Meeting which is being held from May 7th - 11th, 2017 in Baltimore, US.

New clinical focus on disease-modifying drugs for diabetic eye disease 

ThromboGenics has made important progress in building a new pipeline of novel and unique compounds targeting disease modifying treatments for diabetic eye disease with 4 development programs targeting all key segments of this disease area: non-proliferative and proliferative diabetic retinopathy (NPDR/PDR), with or without diabetic macula edema (DME).

The Company's pipeline of novel drug candidates are THR-317 a PlGF inhibitor developed for treating Diabetic Macular Edema (DME), THR-409 (ocriplasmin) targeting total PVD with Non Proliferative Diabetic Retinopathy patients, THR-149 a selective plasma kallikrein inhibitor being developed to treat the edema associated with Diabetic Retinopathy (DR), and THR-687, an integrin antagonist, which has potential utility for treating a broad range of diabetic eye diseases.

"We are pleased to have the opportunity to meet to share, discuss and validate our cutting-edge research in the field of diabetic eye disease with the global vision research community at this year's ARVO Meeting," said Dr Patrik De Haes, CEO of ThromboGenics nv. "Diabetic eye disease, in its various expressions, represents a significant disease area where there is a clear unmet medical need and a strong demand for improved or add-on treatment options. At ThromboGenics, we have multiple new therapies under development, each with the potential to differentiate and improve on the current standard of care for a range of diabetic eye disease indications."

ThromboGenics is currently recruiting patients in two Phase II clinical trials in Europe and the US with THR-409 and THR-317. It plans to initiate two further Phase I/IIa clinical trials around year end and early 2018 with THR-687 and THR-149 respectively.  The company expects to deliver first Phase II data in H1 2018.  

ARVO 2017 Ocriplasmin data presentations underwrite continued interest 

ThromboGenics pioneered the drug class of pharmacological vitreolysis with the development of Jetrea, the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction, in over 50 countries globally.  Since its first introduction in early 2013, over 25,000 patients have received a treatment with Jetrea.

Please click here for a complete overview of all ThromboGenics related preclinical and clinical data communications during ARVO 2017.

About ThromboGenics 

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

Early 2017, ThromboGenics enrolled its first patient in a Phase II clinical study evaluating THR- 317, a PIGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments.

ThromboGenics is also conducting a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was inlicensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.  

More information is available at www.thrombogenics.com

Important information about forward-looking statements 

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.  

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. 

For further information please contact:
ThromboGenics
Wouter Piepers,
Global Head of Corporate Communications & IR
+32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson
David Dible/Sylvie Berrebi
Tel: +44-20-7282-9571
david.dible@citigatedr.co.uk
sylvie.berrebi@citigatedr.co.uk

SOURCE ThromboGenics